PCRX Pacira BioSciences Inc.

38.1
+1.49  (+4%)
Previous Close 36.61
Open 36.84
Price To Book 4.64
Market Cap 1,586,297,272
Shares 41,635,099
Volume 883,962
Short Ratio
Av. Daily Volume 854,093
Stock charts supplied by TradingView

NewsSee all news

  1. Pacira BioSciences Set to Join S&P SmallCap 600

    NEW YORK, Sept. 24, 2019 /PRNewswire/ -- Pacira BioSciences Inc. (NASD: PCRX) will replace Shutterfly Inc. (NASD: SFLY) in the S&P SmallCap 600 effective prior to the open of trading on Monday, September 30. Apollo

  2. Pacira BioSciences Appoints Chris Christie to Board of Directors

    PARSIPPANY, N.J., Sept. 19, 2019 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), a leading provider of innovative non-opioid pain management options, today announced the appointment of Christopher J.

  3. Pacira BioSciences Completes Enrollment in Multicenter Registration Study of EXPAREL® in Pediatric Patients

    PARSIPPANY, N.J., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), a leading provider of innovative non-opioid pain management options, today announced that it has reached full enrollment of

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Approved October 31, 2011.
EXPAREL
Postsurgical pain
Approval announced April 6, 2018.
EXPAREL
Post surgical pain
Phase 3 completion of enrolment announced September 17, 2019 with data due 4Q 2019.
EXPAREL - pediatric patients
Postoperative Pain Management

Latest News

  1. Pacira BioSciences Set to Join S&P SmallCap 600

    NEW YORK, Sept. 24, 2019 /PRNewswire/ -- Pacira BioSciences Inc. (NASD: PCRX) will replace Shutterfly Inc. (NASD: SFLY) in the S&P SmallCap 600 effective prior to the open of trading on Monday, September 30. Apollo

  2. Pacira BioSciences Appoints Chris Christie to Board of Directors

    PARSIPPANY, N.J., Sept. 19, 2019 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), a leading provider of innovative non-opioid pain management options, today announced the appointment of Christopher J.

  3. Pacira BioSciences Completes Enrollment in Multicenter Registration Study of EXPAREL® in Pediatric Patients

    PARSIPPANY, N.J., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), a leading provider of innovative non-opioid pain management options, today announced that it has reached full enrollment of